XML 54 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Mar. 21, 2016
Summary of Significant Accounting Policies (Details) [Line Items]        
Common stock, par value (in Dollars per share)       $ 0.001
Common stock authorized (in Shares)       360,000,000
Cash and cash equivalents $ 85,265 $ 5,828,548    
Restricted cash equivalents $ 1,306,463 $ 736,667    
Account receivable 71.89% 33.38%    
Total revenues percentage 93.22% 46.24%    
Impairment of equity investments $ 0   $ 0  
Labor pension fund percentage 6.00%      
Percentage of monthly contribution 6.00%      
Employee benefits amount $ 13,031 $ 11,375    
Employee stock-based compensation expenses 1,241,930 2,675,205    
Non-employee stock-based compensation expenses $ 5,794,848 $ 2,631,550    
Benefit percentage 50.00%      
Biokey [Member]        
Summary of Significant Accounting Policies (Details) [Line Items]        
Account receivable 16.62%      
GenePharm, Inc [Member]        
Summary of Significant Accounting Policies (Details) [Line Items]        
Account receivable   37.48%